|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Petrelli F, Ardito R, Ghidini A, Zaniboni
A, Ghidini M, Barni S and Tomasello G: Different toxicity of
cetuximab and panitumumab in metastatic colorectal cancer
treatment: A systematic review and meta-analysis. Oncology.
94:191–199. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marin JJG, Romero MR, Blazquez AG, Herraez
E, Keck E and Briz O: Importance and limitations of chemotherapy
among the available treatments for gastrointestinal tumours.
Anticancer Agents Med Chem. 9:162–184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Newman DJ and Cragg GM: Natural products
as sources of new drugs from 1981 to 2014. J Nat Prod. 79:629–661.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aiello P, Consalvi S, Poce G, Raguzzini A,
Toti E, Palmery M, Biava M, Bernardi M, Kamal MA, Perry G and
Peluso I: Dietary flavonoids: Nano delivery and nanoparticles for
cancer therapy. Semin Cancer Biol. 69:150–165. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kopustinskiene DM, Jakstas V, Savickas A
and Bernatoniene J: Flavonoids as anticancer agents. Nutrients.
12:4572020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rossi M, Negri E, Talamini R, Bosetti C,
Parpinel M, Gnagnarella P, Franceschi S, Dal Maso L, Montella M,
Giacosa A and La Vecchia C: Flavonoids and colorectal cancer in
Italy. Cancer Epidemiol Biomarkers Prev. 15:1555–1558. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang ZJ, Ohnaka K, Morita M, Toyomura K,
Kono S, Ueki T, Tanaka M, Kakeji Y, Maehara Y, Okamura T, et al:
Dietary polyphenols and colorectal cancer risk: The Fukuoka
colorectal cancer study. World J Gastroenterol. 19:2683–2690. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ni T, He Z, Dai Y, Yao J, Guo Q and Wei L:
Oroxylin A suppresses the development and growth of colorectal
cancer through reprogram of HIF1α-modulated fatty acid metabolism.
Cell Death Dis. 8:e28652017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park MH, Hong JE, Park ES, Yoon HS, Seo
DW, Hyun BK, Han SB, Ham YW, Hwang BY and Hong JT: Anticancer
effect of tectochrysin in colon cancer cell via suppression of
NF-kappaB activity and enhancement of death receptor expression.
Mol Cancer. 14:1242015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao Y, Fan D, Ru B, Cheng KW, Hu S, Zhang
J, Li ETS and Wang M: 6-C-(E-phenylethenyl)naringenin induces cell
growth inhibition and cytoprotective autophagy in colon cancer
cells. Eur J Cancer. 68:38–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dowden H and Munro J: Trends in clinical
success rates and therapeutic focus. Nat Rev Drug Discov.
18:495–496. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu L, Li XH, Ma XX, Tan WH, Ma WZ, Shen
YF, Khan A, Zhou ZH and Yang ZY: (±)-Involucrasins A and B, two
pairs of flavanone enantiomers from Shuteria involucrata and
their inhibitory effects on the proliferation of various cancer
cell lines. J Asian Nat Prod Res. 24:641–647. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao Y, Cai J, Shi K, Li H, Du J, Hu D,
Liu Z and Wang W: Germacrone induces lung cancer cell apoptosis and
cell cycle arrest via the Akt/MDM2/p53 signaling pathway. Mol Med
Rep. 23:4522021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song M, Bode AM, Dong Z and Lee MH: AKT as
a therapeutic target for cancer. Cancer Res. 79:1019–1031. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gupta A, Shah K, Oza MJ and Behl T:
Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for
cancer treatment. Biomed Pharmacother. 109:484–492. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miyashita T, Krajewski S, Krajewska M,
Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor
suppressor p53 is a regulator of bcl-2 and bax gene expression in
vitro and in vivo. Oncogene. 9:1799–1805. 1994.PubMed/NCBI
|
|
20
|
Miyashita T and Reed JC: Tumor suppressor
p53 is a direct transcriptional activator of the human bax gene.
Cell. 80:293–299. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Taylor WR and Stark GR: Regulation of the
G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Badie C, Bourhis J, Sobczak-Thépot J,
Haddada H, Chiron M, Janicot M, Janot F, Tursz T and Vassal G:
p53-dependent G2 arrest associated with a decrease in cyclins A2
and B1 levels in a human carcinoma cell line. Br J Cancer.
82:642–650. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tu Y, Chen L, Ren N, Li B, Wu Y, Rankin
GO, Rojanasakul Y, Wang Y and Chen YC: Standardized saponin extract
from baiye No.1 tea (camellia sinensis) flowers induced S phase
cell cycle arrest and apoptosis via AKT-MDM2-p53 signaling pathway
in ovarian cancer cells. Molecules. 25:35152020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bunz F, Dutriaux A, Lengauer C, Waldman T,
Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B:
Requirement for p53 and p21 to sustain G2 arrest after DNA damage.
Science. 282:1497–1501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hers I, Vincent EE and Tavaré JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol
K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, et al: Growth
retardation and increased apoptosis in mice with homozygous
disruption of the Akt1 gene. Genes Dev. 15:2203–2208. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matthews HK, Bertoli C and de Bruin RAM:
Cell cycle control in cancer. Nat Rev Mol Cell Biol. 23:74–88.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oakes V, Wang W, Harrington B, Lee WJ,
Beamish H, Chia KM, Pinder A, Goto H, Inagaki M, Pavey S and
Gabrielli B: Cyclin A/Cdk2 regulates Cdh1 and claspin during late
S/G2 phase of the cell cycle. Cell Cycle. 13:3302–3311. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Singh P and Lim B: Targeting apoptosis in
cancer. Curr Oncol Rep. 24:273–284. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peña-Blanco A and García-Sáez AJ: Bax, Bak
and beyond-mitochondrial performance in apoptosis. Febs J.
285:416–431. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang H, Luo J and Lei H: The roles of
mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A
review. Exp Eye Res. 217:1089102022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zafar A, Wang W, Liu G, Xian W, McKeon F,
Zhou J and Zhang R: Targeting the p53-MDM2 pathway for
neuroblastoma therapy: Rays of hope. Cancer Lett. 496:16–29. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Afshari K, Haddadi NS, Haj-Mirzaian A,
Farzaei MH, Rohani MM, Akramian F, Naseri R, Sureda A, Ghanaatian N
and Abdolghaffari AH: Natural flavonoids for the prevention of
colon cancer: A comprehensive review of preclinical and clinical
studies. J Cell Physiol. 234:21519–21546. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Butler MS: Natural products to drugs:
Natural product-derived compounds in clinical trials. Nat Prod Rep.
25:475–516. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Slika H, Mansour H, Wehbe N, Nasser SA,
Iratni R, Nasrallah G, Shaito A, Ghaddar T, Kobeissy F and Eid AH:
Therapeutic potential of flavonoids in cancer: ROS-mediated
mechanisms. Biomed Pharmacother. 146:1124422022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hua H, Zhang H, Chen J, Wang J, Liu J and
Jiang Y: Targeting Akt in cancer for precision therapy. J Hematol
Oncol. 14:1282021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dent R, Oliveira M, Isakoff SJ, Im SA,
Espié M, Blau S, Tan AR, Saura C, Wongchenko MJ, Xu N, et al: Final
results of the double-blind placebo-controlled randomized phase 2
LOTUS trial of first-line ipatasertib plus paclitaxel for
inoperable locally advanced/metastatic triple-negative breast
cancer. Breast Cancer Res Treat. 189:377–386. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bykov VJN, Eriksson SE, Bianchi J and
Wiman KG: Targeting mutant p53 for efficient cancer therapy. Nat
Rev Cancer. 18:89–102. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Duffy MJ, Synnott NC and Crown J: Mutant
p53 as a target for cancer treatment. Eur J Cancer. 83:258–265.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lai CW, Xie C, Raufman JP and Xie G:
Targeting post-translational regulation of p53 in colorectal cancer
by exploiting vulnerabilities in the p53-MDM2 axis. Cancers
(Basel). 14:2192022. View Article : Google Scholar : PubMed/NCBI
|
